Marshall Wace
SPRO icon

Marshall Wace’s Spero Therapeutics SPRO Stock Holding History

Marshall Wace’s Portfolio SPRO Stock Details SPRO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-157,072
Closed -$368K – 3709
2026
Q1 		$368K Buy
+157,072
New +$373K ﹤0.01% 2587
2023
Q2 		– Sell
-64,388
Closed -$93.4K – 2940
2023
Q1 		$93.4K Buy
64,388
+13,471
+26% +$22.6K ﹤0.01% 2505
2022
Q4 		$88.1K Sell
50,917
-135,653
-73% -$253K ﹤0.01% 2803
2022
Q3 		$374K Buy
186,570
+150,201
+413% +$149K ﹤0.01% 2857
2022
Q2 		$27K Buy
36,369
+10,342
+40% +$30.1K ﹤0.01% 3352
2022
Q1 		$227K Buy
+26,027
New +$267K ﹤0.01% 3059
2019
Q3 		– Sell
-17,699
Closed -$204K – 1913
2019
Q2 		$204K Buy
17,699
+14,625
+476% +$176K ﹤0.01% 1245
2019
Q1 		$39K Buy
+3,074
New +$32.6K ﹤0.01% 1563

Other funds holding SPRO

GP
GSK plc London $602M AUM
P
Pfizer New York $170M AUM 191.09% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
AI
Alphabet Inc Mountain View, California $99.1B AUM 124.46% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $1.28T AUM 58.89% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Raymond James Financial
Raymond James Financial St Petersburg, Florida $369B AUM 28.27% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Marshall Wace's SPRO Position: Q2 2026 in Review

Marshall Wace sold out of Spero Therapeutics (SPRO) in Q2 2026, closing a stake of 157,072 shares — an estimated $368K sold.

Marshall Wace first reported a position in SPRO in Q1 2019 and held it in 8 quarters. The position peaked at $374K in Q3 2022. 60 funds tracked by Wall St. Rank hold SPRO as of Q2 2026.

  • Marshall Wace reported no remaining Spero Therapeutics position as of Q2 2026 after selling out during the quarter.
  • Marshall Wace sold 157,072 Spero Therapeutics shares in Q2 2026, an estimated $368K.
  • Marshall Wace first reported a position in Spero Therapeutics in Q1 2019 and held it in 8 quarters.
  • Marshall Wace's Spero Therapeutics position peaked at $374K in Q3 2022.
  • 60 funds tracked by Wall St. Rank held Spero Therapeutics as of Q2 2026.

Based on Marshall Wace's 13F filing for Q2 2026, filed 13 Aug 2026.